AC
CTKB icon

AXQ Capital’s Cytek Biosciences CTKB Stock Holding History

AXQ Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$86.1K Buy
19,708
+584
+3% +$2.76K 0.01% 887
2025
Q4 		$96.6K Buy
+19,124
New +$88.8K 0.02% 656

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AXQ Capital's CTKB Position: Q1 2026 in Review

AXQ Capital increased its Cytek Biosciences (CTKB) stake by 3.1% in Q1 2026, buying an estimated $2.76K and bringing the position to 19,708 shares worth $86.1K. The position accounts for 0.01% of the portfolio, ranked #887.

AXQ Capital first reported a position in CTKB in Q4 2025 and has held it in 2 quarters since. The position peaked at $96.6K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • AXQ Capital held 19,708 shares of Cytek Biosciences worth $86.1K as of Q1 2026.
  • AXQ Capital bought 584 Cytek Biosciences shares in Q1 2026, an estimated $2.76K.
  • Cytek Biosciences made up 0.01% of AXQ Capital's portfolio in Q1 2026, its #887 holding.
  • AXQ Capital first reported a position in Cytek Biosciences in Q4 2025 and has held it in 2 quarters since.
  • AXQ Capital's Cytek Biosciences position peaked at $96.6K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.